Form 4: Iovance Biotherapeutics Executive Granted Stock Options and Restricted Stock Units

Daniel Gordon Kirby, Chief Commercial Officer of Iovance Biotherapeutics, received stock options, restricted stock units (RSUs), and performance stock units (PSUs) on February 10, 2025.

Summary

• Daniel Gordon Kirby, the Chief Commercial Officer of Iovance Biotherapeutics, was granted stock options, restricted stock units (RSUs), and performance stock units (PSUs) on February 10, 2025.
• The stock options allow Kirby to purchase 35,000 shares of common stock at an exercise price of $5.32 per share.
• The RSUs represent a contingent right to receive 120,000 shares of Iovance's common stock.
• The PSUs could convert into up to 150,000 shares of common stock, contingent upon achieving certain financial milestones.
• The vesting schedule for the options and RSUs is one-third on the one-year anniversary of the grant date, and the remaining two-thirds vesting in equal quarterly installments over the subsequent two years, provided Kirby remains employed by Iovance.
• The PSUs will vest on the date Iovance publicly announces its 2025 financial results by filing its Form 10-K with the SEC.

Sentiment

Score: 7

Explanation: The document indicates standard executive compensation practices, which is generally viewed neutrally to positively as it aligns management interests with shareholders. The sentiment is moderately positive as it suggests the company is investing in its leadership.

Positives

• The grants of stock options, RSUs, and PSUs align the executive's interests with those of the shareholders.
• The vesting schedule incentivizes continued employment and performance.

Risks

• The value of the stock options, RSUs, and PSUs is dependent on the future performance of Iovance's stock price.
• The PSUs are contingent on achieving certain financial milestones, which may not be met.

Future Outlook

The vesting of the PSUs is contingent upon the achievement of certain financial milestones and the public announcement of Iovance's 2025 financial results.

Industry Context

This type of equity compensation is common in the biotechnology industry to attract and retain key executives and align their interests with those of shareholders.

Comparison to Industry Standards

• Equity grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Kite Pharma (acquired by Gilead), Juno Therapeutics (acquired by Celgene), and Adaptimmune also utilize stock options, RSUs, and PSUs to incentivize their leadership teams.
• The vesting schedules and performance metrics associated with these grants are typically aligned with industry best practices to drive long-term value creation.

Stakeholder Impact

• Shareholders: The equity grants align management's interests with shareholder value creation.
• Employees: The grants may serve as an incentive for other employees as well, knowing that management is incentivized to improve the company's performance.

Next Steps

• The executive must continue employment with Iovance to fully vest in the stock options and RSUs.
• Iovance must achieve the financial milestones for the PSUs to vest.
• Iovance will publicly announce its 2025 financial results, which will determine the vesting of the PSUs.

Key Dates